Home treatment for chronic pain using LG Medipain device
Clinical Effect of LG Medipain for Managing Chronic Pain Disorders: A Prospective Observational Study
This study tests if using the LG Medipain device at home can help people with chronic pain feel better by changing their pain signals without needing to go to the hospital often.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Seoul National University Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05165901 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of the LG Medipain device, which utilizes Scrambler Therapy, a non-invasive neuromodulation technique, for managing chronic pain disorders. The device aims to convert pain signals into non-pain signals, potentially providing lasting pain relief without the need for frequent hospital visits. Participants will use the device at home while continuing their current pain medication regimen. The study focuses on patients suffering from various types of chronic pain, including neuropathic and nociceptive pain.
Who should consider this trial
Good fit: Ideal candidates are adults aged 19 and older with chronic pain lasting over three months and a pain score of 4 or higher.
Not a fit: Patients who have not experienced pain relief from previous Scrambler Therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide significant pain relief for patients with chronic pain, improving their quality of life.
How similar studies have performed: Previous studies on Scrambler Therapy have shown promising results in pain relief, indicating that this approach has potential based on existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic pain disease (pain over 3 months) as an adult 19 years of age or older * Patients with 11-pointed NRS pain score ≥ 4 for the corresponding pain on the day of admission * Patients taking oral pain treatment drugs in the same type and dose up to 1 month before participating in the study, and taking the same medication until 1 month after participating in the study (at the time of obtaining the primary endpoint) * Those who voluntarily and in writing consent to participate in the study * A person who has agreed in writing to return the Scrambler Therapy device * By the classification of pain disorder, patients include with nociceptive pain such as joint pain, myofascial pain syndrome and with neuropathic pain such as postherpetic neuralgia, peripheral nerve injury and nerve entrapment syndrome and with mixed pain. Exclusion Criteria: * Refusal of the patient * In case pain relief effect was not obtained in the past Scrambler Therapy * Patients currently undergoing Scrambler therapy for pain control at outpatient clinics at the Pain Center * Patients who had previously taken Scrambler Therapy 6 months before participating in the study * In case of systemic infection or local infection in the area around the treatment (the patch attachment site) * Patients who has cognitive decline that cannot understand the contents of the Numeric Pain Rating (NRS), questionnaire, and scrambler self application method * If it is difficult to self-administer 10 scrambler treatments for 2 weeks during the treatment period * Women during pregnancy * In case of implantation of a pacemaker, brain stimulator, etc. * Those who are not suitable for this clinical trial under the judgment of other investigators
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Jee Yoon Moon, Pf
- Email: jymoon0901@gmail.com
- Phone: +82 2 2072 2462
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.